Printer Friendly

Perrigo Company announces addition of USD93m ophthalmic ointment and solution products portfolio.

M2 PHARMA-June 18, 2013-Perrigo Company announces addition of USD93m ophthalmic ointment and solution products portfolio(C)2013 M2 COMMUNICATIONS

Healthcare company Perrigo Company (NYSE:PRGO) (TASE:PRGO) announced on Monday that it has completed its acquisition of an ophthalmic sterile ointment and solution product portfolio for an upfront cash payment of approximately USD93m.

The seller is Fera Pharmaceuticals LLC and its affiliates (Fera).

Additionally, the transaction includes potential contingent payments of approximately USD36m, certain of which relate to Perrigo securing additional product rights from Fera.

Perrigo Company's acquired portfolio includes nine prescription ANDA products, which generated more than USD30m in net revenues during calendar year 2012.

In conjunction, Perrigo expects to receive a tax benefit from the acquisition, the net present value of which is estimated to be approximately USD20m.

((Comments on this story may be sent to>PDJune 18, 2013>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 18, 2013
Previous Article:Rexahn Pharmaceuticals Inc wins patent for novel anti-cancer compounds in the US.
Next Article:Transition Therapeutics Inc reports exercise of rights to TT-401 by Eli Lilly and Company.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters